Yükleniyor... / Loading...
Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
Bu çalışma, insan nefesindeki uçucu organik bileşiklerin (volatile organic compounds) analiziyle iyi huylu ve kötü huylu akciğer nodüllerinin (pulmonary nodules) ayırt edilip edilemeyeceğini araştırmaktadır. Çalışmaya, tomografide 5-30 mm boyutunda akciğer nodülü saptanan ve nodül tipini belirlemek için cerrahi gereken 18-80 yaş arası hastalar katılabilmektedir. Faz uygulanmayan bir çalışma olarak yürütülmekte ve halen katılımcı almaktadır.
Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.
Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.
Inclusion Criteria: * 18-80 years old; * Pulmonary nodules were detected through low-dose spiral CT, chest CT conventional scan, or high-resolution thin-layer CT examination, with a maximum diameter of 5-30 mm, including solid nodules and ground glass nodules; * Patients require pulmonary nodule resection to define the type of nodule pathology; * The Patients have not yet used any drugs for tumor treatment; * Patients and/or family members are able to understand the research protocol and are willing to participate in this study, providing written informed consent. Exclusion Criteria: * The maximum diameter of pulmonary nodules is greater than 30 mm; * Patients are unable to determine the pathological diagnosis of pulmonary nodules after surgical resection or biopsy; * Patients with recurrent lung cancer; * Patients who have undergone lung transplantation or lobectomy; * Individuals who currently or have a history of malignant tumors; * Patients in the acute phase of inflammation or in need of intensive care in the above selected disease groups; * Individuals with severe liver and kidney dysfunction; * Mental illness patients (such as severe dementia, schizophrenia, severe depression, manic depressive psychosis, etc.); * Confirmed HIV patients; * Pregnant or lactating women; * Patients or family members are unable to understand the conditions and objectives of this study. * The patient is unwilling or unable to personally sign the informed consent form.